Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s share price crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $30.13 and traded as low as $28.21. Nanobiotix shares last traded at $28.54, with a volume of 103,793 shares.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Guggenheim started coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Nanobiotix currently has an average rating of “Moderate Buy” and a consensus target price of $46.67.
Get Our Latest Stock Analysis on NBTX
Nanobiotix Stock Down 6.9%
The company has a 50 day moving average price of $30.13 and a two-hundred day moving average price of $34.24.
About Nanobiotix
Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.
Further Reading
- Five stocks we like better than Nanobiotix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
